Drug Trial Radar · NCT07325240
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 21, 2025
Primary completion
Jul 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alcon Research
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solutionDrug
Subjects will receive netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005% in one eye and compare it to latanoprost 0.005% in the contralateral eye
Latanoprost 0.005% Ophthalmic SolutionDrug
latanoprost 0.005% solution will be applied in the contralateral eye, once daily, QD (PM) for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in mean Intraocular Pressure (IOP)Time frame: Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline
- Change in mean IOPTime frame: Change in mean IOP after 2 weeks of treatment with Rocklatan compared to baseline
- Change in mean IOPTime frame: Change in mean IOP from baseline after 2 weeks of treatment with latanoprost minus change in mean IOP from baseline after 2 weeks of treatment with Rocklatan
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.